

Bal Pharma Limited

To, The Manager-Listing Bombay Stock Exchange Ltd Mumbai.

7.04.2016

Dear Sir,

Sub: Investor Grievances. Ref: Scrip Code 524824.

With reference to the above and pursuant to Regulation 13(3) of SEBI (LODR) Regulations, 2015, we furnish to the exchange the following statement of investor grievances as on the quarter ended 31.03.2016.

Sl No	Details	Status
01	Number of complaints outstanding at the beginning of the quarter.	0
02	Number of complaints received during the quarter.	0
03	Number of complaints resolved during the quarter .	0
04	Number of complaints pending at the end of the quarter.	0

Please take the same on record.

Thanking You.

For Bal Pharma Limited

Authorised Signatory.

Enclosed: Letter of confirmation issued by our R&T agent i.e TSR Darashaw Ltd.







Ref No.: ISS/BMQT4/1516

April 7, 2016

Bal Pharma Ltd. 5th Floor, Lakshminarayan Complex, 10/1, Palace Road, Bangalore-560052

Dear Sir,

Sub: Extract of the Correspondence report required as per Regulation 13(3)
of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 for
the quarter 01.01.2016 to 31.03.2016

As per your request, the required information is given below:

Serial No.	Details of Investor Complaints	No. Of Complaints
1	Pending as on 01.01.2016	0
2	Received during the quarter ended 31.03.2016	Ů
3	Disposed off during the quarter ended 31.03.2016	0
. 4	Unresolved at the end of the quarter ended 31.03.2016	. 0.

Thanking you,

Yours faithfully,

For TSR Darashaw Ltd.

(Smita Rao)

Senior Associate Manager

TSR DARASHAW LIMITED